Dublin, June 26, 2019 (GLOBE NEWSWIRE) -- The "Depressive Disorders: Pipeline Review, Developer Landscape and Competitive Insights" report has been added to ResearchAndMarkets.com's offering.
The Depressive Disorders Market: Pipeline Review, Developer Landscape and Competitive Insights report provides an extensive study on the marketed (approved post-2010), clinical and preclinical molecules available / being developed, for the treatment of depressive disorders.
Depression is a chronic medical condition characterized by a persistent feeling of sadness and lack of interest in external stimuli. It is a commonly diagnosed mental health disorder and is considered among the leading causes of disability across the globe. It has been estimated that over 300 million people (considering all age groups) suffer from depression worldwide.
Further, depression and other depressive disorders are projected to be responsible for an economic burden of up to USD 210 billion per year in the US. Despite the high prevalence and significant impact of this disease, less than 50% of affected individuals receive treatment in high-income countries; this figure stands at less than 10% for low-income countries.
According to the World Health Organization, barriers to effective care for depression and other depressive disorders, include lack of resources, lack of trained healthcare professionals, inaccurate diagnoses of the condition and the social stigma associated with to mental health disorders.
A number of blockbuster drugs are available to treat depression; these include Prozac and Celexa (approved in 1980s), Paxil and Zoloft (approved in 1990s), and Lexapro and Cymbalta (approved in 2000s). These drugs work by modulating monoamine levels in the brain, a mechanism that has been re-evaluated and improved across the last six decades.
Since the 1950s, around 30 branded drugs and more than 150 generic products have been approved by the FDA to treat various forms of depression. Currently, selective serotonin reuptake inhibitors (SSRIs) form the mainstay of treatment options for depression. Despite the availability of generics and other branded drugs, patients have voiced the need for better antidepressants as currently available SSRIs take a long time (few weeks) to demonstrate therapeutic benefit.
In addition, around 50% of treated patients do not respond to the first prescribed antidepressant and need to go through months of trial and error-based therapy regimens before an appropriate drug is identified to treat their underlying condition. Further, there are many patients who never respond to any of the available therapeutic strategies, highlighting an urgent need for effective treatment solutions for depression.
Several stakeholders in the pharmaceutical industry are currently engaged in efforts to develop various types of interventions and drug/therapy candidates with novel mechanisms of action to treat depression.
Scope of the Report
Key Topics Covered:
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of Depression and Depressive Disorders
3.2. Signs and Symptoms of Depression
3.3. Types of Depression
3.4. Epidemiology of Depression
3.5. Causes of Depression
3.6. Diagnosis of Depression
3.7. Current Treatment Paradigms
3.7.1. Pharmacological Treatment
3.7.2. Psychological Treatment
3.7.3. Other Treatments
3.8. Innovative Therapeutic Strategies
4. PIPELINE REVIEW: MARKETED AND CLINICAL STAGE DRUGS
4.1. Chapter Overview
4.2. Depressive Disorders: Marketed and Development Pipeline
4.3. Depressive Disorders: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Type of Depressive Disorder
4.3.4. Analysis by Drug Class
4.3.5. Analysis by Mechanism of Action
4.3.6. Analysis by Route of Administration
4.3.7. Analysis by Dosing Frequency
4.3.8. Analysis by Type of Therapy
4.3.9. Grid Analysis: Distribution by Type of Depressive Disorder, Phase of Development and Mechanism of Action
4.4. Depressive Disorders: List of Drug Developers
4.4.1. Analysis by Year of Establishment of Developer
4.4.2. Analysis by Geographical Location
4.4.3. Analysis by Company Size and Geographical Location
4.4.4. Leading Developers
4.4.5. Grid Analysis: Distribution by Location, Company Size and Mechanism of Action of Pipeline Drugs
5. CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS
5.1. Chapter Overview
5.2. Depressive Disorders: Discontinued Drugs
5.2.1. Analysis by Year of Discontinuation
5.2.2. Analysis by Phase of Discontinuation
5.2.3. Analysis by Mechanism of Action
5.2.4. Analysis by Type of Depressive Disorder
5.2.5. Key Players
5.2.6. Analysis by Reason for Discontinuation
5.3. Depressive Disorders: Discontinued Clinical Trials
5.3.1. Year-wise Trend of Discontinued Trials
5.3.2. Analysis of Discontinued Clinical Trials by Phase of Development
5.3.3. Analysis of Discontinued Clinical Trials by Sponsor / Collaborator
5.3.4. Analysis of Discontinued Clinical Trials by Geography
5.4. Concluding Remarks
6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models
6.3. Depressive Disorders: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnerships
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Area of Focus
6.3.4. Analysis by Type of Depressive Disorder
6.3.5. Analysis by Geographical Activity
6.3.6. Most Active Players
7. FUNDING AND INVESTMENT ANALYSIS
7.1. Chapter Overview
7.2. Types of Funding
7.3. Depressive Disorders: Funding and Investment Analysis
7.3.1. Analysis by Number of Instances
7.3.2. Analysis by Amount Invested
7.3.3. Analysis by Type of Funding
7.3.4. Most Active Players
7.3.5. Most Active Investors
7.4. Concluding Remarks
8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Depressive Disorders: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Phase
8.3.3. Analysis by Recruitment Status
8.3.4. Analysis by Type of Sponsor / Collaborator
8.3.5. Analysis by Type of Depressive Disorder
8.3.6. Analysis by Mechanism of Action
8.3.7. Most Active Players
8.3.8. Analysis by Number of Clinical Trials and Geography
8.3.9. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
8.3.10. Analysis by Number of Clinical Trials, Mechanism of Action and Geography
8.3.11. Analysis by Number of Clinical Trials, Mechanism of Action, Trial Phase and Geography
8.3.12. Analysis by Number of Clinical Trials, Type of Depressive Disorder and Geography
8.3.13. Analysis by Number of Clinical Trials, Type of Depressive Disorder, Trial Phase and Geography
8.3.14. Analysis by Enrolled Patient Population and Geography
8.3.15. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
8.3.16. Analysis by Enrolled Patient Population, Type of Depressive Disorder and Geography
8.3.17. Analysis by Enrolled Patient Population, Type of Depressive Disorder, Trial Phase and Geography
8.3.18. Analysis by Enrolled Patient Population, Mechanism of Action and Geography
8.3.19. Analysis by Enrolled Patient Population, Mechanism of Action, Trial Phase and Geography
9. CLINICAL TRIAL ENDPOINTS ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Overview of Most Common Primary Endpoints
9.4. Primary Endpoints Evaluated for Major Depressive Disorder: Comparative Analysis of Late-Stage Drugs
9.5. Primary Endpoints Evaluated for Bipolar Disorder: Comparative Analysis of Late-Stage Drugs
9.6. Primary Endpoints Evaluated for Other Types of Depressive Disorder: Comparative Analysis of Late-Stage Drugs
9.7. Concluding Remarks
10. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Methodology
10.2.1. Assumptions and Key Parameters
10.3. Key Insights
10.3.1. Clinical and Commercial Attractiveness Analysis: Major Depressive Disorder
10.3.2. Clinical and Commercial Attractiveness Analysis: Bipolar Disorder
10.3.3. Clinical and Commercial Attractiveness Analysis: Other Types of Depressive Disorder
11. KEY COMMERCIALIZATION STRATEGIES
11.1. Chapter Overview
11.2. Successful Drug Launch Strategy: Framework
11.3. Successful Drug Launch Strategy: Product Differentiation
11.4. Commercialization Strategies Adopted Based on Development Stage of Product
11.5. Approved Molecules for Treating Depressive Disorders
11.5.1. Abilify Mycite
11.5.2. Abilify Maintena
11.5.3. Rexulti
11.5.4. Vraylar
11.5.5. Trintellix
11.5.6. Fetzima
11.5.7. Latuda
11.5.8. Viibryd
11.6. Key Commercialization Strategies Adopted by the Companies Focused on Depressive Disorders
11.6.1. Strategies Adopted Before the Approval of Drug
11.6.1.1. Participation in Global Events
11.6.2. Strategies Adopted During / Post Approval of Drug
11.6.2.1. Collaboration with Internal Stakeholders and Pharmaceutical Firms
11.6.2.2. Awareness through Product Websites
11.6.2.3. Advertising Directly to Consumers
11.6.3. Strategies Adopted Near Patent Expiry of Drug
11.6.3.1. Approval of Drug in Multiple Geographies
11.6.3.2. Approval of Drug for Multiple Indications
11.7. Concluding Remarks
12. DIGITAL THERAPEUTICS FOR DEPRESSIVE DISORDERS
12.1. Chapter Overview
12.2. An Overview on Digital Therapeutics
12.3. Development and Commercialization Pathway for Digital Therapeutics
12.3.1. Discovery and Preclinical Research
12.3.2. Clinical Trials and Validation
12.3.3. Engaging Insurance Providers / Payers
12.3.4. Distribution and Marketing
12.4. Digital Therapeutics for Depressive Disorders
12.4.1. Standalone Software Applications
12.4.2. Personal Coaching
12.4.3. AI Support
12.4.4. Gaming Solutions
13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/rq6y27
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Mental Disorders Drugs